肝硬化合并糖尿病患者血糖管理专家共识

Expert consensus on the management of diabetes mellitus in patients with liver cirrhosis

针对肝硬化患者糖尿病高流行率和非酒精性脂肪性肝病相关肝硬化日益增多的趋势,肝硬化合并糖尿病人群面临的诊断和治疗问题越来越突出。基于此,中国医药生物技术协会慢病管理分会组织消化病学、传染病学、内分泌学等领域专家,聚焦肝硬化患者糖尿病的分型和血糖管理,最终形成《肝硬化合并糖尿病患者血糖管理专家共识》。本共识总结了肝硬化合并糖尿病的患病率、发病机制、临床特征和转归,将肝硬化合并糖尿病分为4种类型,明确提出了肝源性糖尿病这一亚型,推荐了在肝硬化患者中进行糖尿病诊断、监测和根据肝功能选择降糖药物的基本原则。

In view of the high prevalence of diabetes mellitus in patients with liver cirrhosis and the increasing trend of non-alcoholic fatty liver disease-associated cirrhosis,the diagnosis and treatment of diabetes mellitus in patients with liver cirrhosis are becoming widespread concerns.Therefore,the Chronic Disease Management Branch,China Pharmaceutical Biotechnology Association,organized multidisciplinary experts from gastroenterology,infective disease,endocrinology,etc,to draw up expert consensus on the management of diabetes mellitus in patients with liver cirrhosis,with focusing on the classification and management of hyperglycemia in cirrhotic patients.The consensus summarizes the prevalence,pathogenesis,clinical setting and prognosis of the concomitant diabetes mellitus in patients with liver cirrhosis,and definitely puts forward a proposal regarding"hepatogenous diabetes"as one of the four subtypes of diabetes mellitus in cirrhotic patients,and further recommends the basic principles for diagnosing and monitoring diabetes mellitus and the selection of antidiabetic drugs based on liver functions in patients with liver cirrhosis.